Primary Lateral Sclerosis (PLS) is a rare, progressive neurodegenerative disorder characterized by selective degeneration of the upper motor neurons in the motor cortex and corticospinal tract. Unlike Amyotrophic Lateral Sclerosis (ALS), PLS spares the lower motor neurons, resulting in a distinct clinical phenotype dominated by spasticity and rigidity without muscle wasting or fasciculations.
The treatment of PLS focuses on symptom management, functional preservation, and improving quality of life. While no disease-modifying therapies are FDA-approved specifically for PLS, emerging treatments targeting underlying pathophysiological mechanisms are under active investigation. This comprehensive guide covers all aspects of PLS management, from pharmacological interventions to rehabilitation and experimental approaches.
The primary objectives of PLS treatment include:
- Reducing spasticity to improve mobility and reduce pain
- Managing pseudobulbar affect (emotional lability)
- Preserving functional abilities as long as possible
- Supporting respiratory function in advanced disease
- Enhancing quality of life through multidisciplinary care
Spasticity is the hallmark symptom of PLS, presenting as a velocity-dependent increase in muscle tone with hyperreflexia. Management follows a stepwise approach:
Baclofen
- Mechanism: GABA-B receptor agonist that inhibits monosynaptic and polysynaptic reflexes in the spinal cord
- Dosing: Start 5-10 mg three times daily, titrate to 30-60 mg/day as needed
- Maximum: Up to 80 mg/day in divided doses
- Adverse effects: Sedation, dizziness, weakness, dry mouth
- Considerations: Abrupt discontinuation should be avoided due to risk of seizures and hallucinations
Tizanidine
- Mechanism: Alpha-2 adrenergic agonist that reduces release of norepinephrine from spinal interneurons
- Dosing: Start 2 mg three times daily, titrate to 8-12 mg/day
- Maximum: 36 mg/day in divided doses
- Adverse effects: Somnolence, dry mouth, dizziness, hepatotoxicity (monitor liver function)
- Considerations: May be particularly effective for nighttime spasticity
Benzodiazepines
- Diazepam: 2-10 mg three times daily; effective but significant sedation
- Clonazepam: 0.5-2 mg at bedtime; useful for nocturnal spasticity
- Mechanism: Enhances GABA-A receptor signaling
- Adverse effects: Significant sedation, cognitive impairment, fall risk
Dantrolene Sodium
- Mechanism: Direct calcium antagonist acting on skeletal muscle
- Dosing: Start 25 mg daily, titrate to 25-100 mg four times daily
- Adverse effects: Hepatotoxicity (requires monitoring), drowsiness, diarrhea
- Considerations: Reserved for severe, refractory spasticity due to hepatotoxicity risk
Gabapentin
- Mechanism: Voltage-gated calcium channel modulation
- Dosing: 300-1200 mg three times daily
- Adverse effects: Dizziness, peripheral edema, cognitive fogging
- Considerations: May help neuropathic pain components
For focal spasticity, botulinum toxin injections provide targeted relief:
- Agents: OnabotulinumtoxinA (Botox), AbobotulinumtoxinA (Dysport), RimabotulinumtoxinB (Myobloc)
- Dosing: Variable by muscle group; typically 25-400 units per session
- Onset: 1-2 weeks post-injection
- Duration: 3-4 months per treatment
- Target muscles: Gastrocnemius, soleus, hamstrings, hip adductors
Pseudobulbar affect (PBA), also called emotional lability, occurs in up to 50% of PLS patients, causing involuntary episodes of crying or laughing.
Dextromethorphan/Quinidine (Nuedexta)
- Mechanism: Quinidine inhibits CYP2D6-mediated dextromethorphan metabolism; dextromethorphan acts on NMDA receptors and sigma-1 receptors
- Dosing: 20 mg/10 mg twice daily
- FDA approval: First and only FDA-approved treatment for PBA
- Adverse effects: Dizziness, nausea, diarrhea, cardiac effects (QT prolongation)
Valbenazine (Ingrezza)
- Mechanism: VMAT2 inhibitor that reduces monoamine uptake
- Dosing: Start 40 mg daily, increase to 80 mg daily after one week
- Adverse effects: Somnolence, QT prolongation
- Considerations: Requires cardiac monitoring in some patients
Tetrabenazine
- Mechanism: VMAT2 inhibitor
- Dosing: 12.5-50 mg three times daily
- Adverse effects: Depression, sedation, parkinsonism
- Considerations: Monitor for suicidal ideation
¶ Muscle Cramps and Pain
Muscle cramps are common in PLS and can be debilitating:
Quinine Sulfate
- Dosing: 200-300 mg three times daily
- Adverse effects: Cinchonism (tinnitus, headache), cardiac arrhythmias
- Considerations: Requires ECG monitoring; limited course recommended
Mexiletine
- Mechanism: Sodium channel blocker
- Dosing: 150-300 mg three times daily
- Adverse effects: Nausea, tremor, cardiac effects
While no therapies are FDA-approved specifically for PLS, several agents approved for ALS show promise:
Riluzole (Rilutek)
- Mechanism: Glutamate antagonist, reduces excitotoxicity
- Dosing: 50 mg twice daily
- Evidence: Demonstrated modest survival benefit in ALS; extrapolated to PLS
- Adverse effects: Nausea, asthenia, liver enzyme elevations
- Considerations: Monitor liver function tests
Edaravone (Radicava)
- Mechanism: Antioxidant, scavenges peroxynitrite radicals
- Dosing: 60 mg IV infusion for 10 consecutive days, then 10-day drug-free periods
- Evidence: FDA-approved for ALS; Phase 3 trial planned for PLS
- Adverse effects: Headache, contusion, gait disturbance
- Considerations: Requires IV access and infusion center visits
AMX0035 (Relyvrio)
- Mechanism: Targets mitochondrial dysfunction and oxidative stress
- Dosing: 1 packet daily, titrating to 2 packets twice daily
- Evidence: FDA-approved for ALS; potential benefit in PLS
- Adverse effects: Diarrhea, nausea, abdominal pain
Several novel therapies are under investigation:
| Agent |
Mechanism |
Development Stage |
Target |
| Antisense oligonucleotides |
Gene silencing |
Phase 1/2 |
Specific genetic mutations |
| Stem cell therapy |
Neuronal replacement |
Phase 1/2 |
Motor cortex |
| Gene therapy |
Genetic correction |
Preclinical |
Hereditary forms |
| Neuroprotective agents |
Multiple |
Phase 2/3 |
General neuroprotection |
Physical therapy is cornerstone of PLS management:
Stretching Programs
- Daily stretching of hip adductors, hamstrings, and calf muscles
- Hold each stretch for 30-60 seconds, repeat 3-4 times
- Prevents contractures and reduces spasticity
Strengthening Exercises
- Focus on maintaining existing muscle strength
- Low-impact exercises: swimming, stationary cycling
- Avoid overexertion that may worsen spasticity
Gait Training
- Balance training to reduce fall risk
- Assistive device training (canes, walkers)
- Floor-to-stand transfers
Aquatic Therapy
- Water provides buoyancy, reducing spasticity
- Warm water (82-88°F) enhances muscle relaxation
- Improves mobility and confidence
Adaptive Equipment
- Long-handled reachers for dressing
- Built-up utensils for eating
- Keyboard adaptations for computer use
Energy Conservation Techniques
- Pacing activities throughout the day
- Prioritizing essential tasks
- Using assistive devices to conserve energy
Home Modifications
- Grab bars in bathroom
- Ramp access if needed
- Accessible shower stalls
¶ Speech and Swallowing Therapy
Dysarthria Management
- Articulation exercises
- Pacing strategies for clearer speech
- Amplification devices if needed
Dysphagia Management
- Swallowing exercises
- Diet modification (soft foods, thickened liquids)
- Safe swallowing techniques
Respiratory compromise occurs in advanced PLS:
Pulmonary Function Monitoring
- Forced vital capacity (FVC) every 3-6 months
- Nocturnal oximetry to detect sleep-disordered breathing
- Cough assist devices for secretion clearance
Support Options
- Non-invasive ventilation (BiPAP) for nocturnal hypoventilation
- Cough-assist devices
- Secretion management
Dietary Considerations
- Maintain adequate caloric intake to prevent weight loss
- High-protein diet to preserve muscle mass
- Adequate fiber and hydration for constipation prevention
- Consider Mediterranean diet for anti-inflammatory benefits
Feeding Support
- PEG tube placement if dysphagia progresses
- Nutritional supplements
- Regular weight monitoring
¶ Surgical and Device-Based Therapies
While primarily used for Parkinson's disease, DBS may have a role in PLS with significant rigidity:
Targets Under Investigation
- GPi (globus pallidus interna)
- Thalamic VIM nucleus
Considerations: Evidence in PLS is limited; requires careful patient selection
Tendon Lengthening
- For severe contractures
- Achilles tendon lengthening for equinus deformity
- Hip flexor releases for flexed posture
Spinal Instrumentation
- For severe scoliosis or kyphosis
- Maintains trunk alignment
- Improves seating comfort
¶ Lifestyle and Supportive Care
Aerobic Exercise
- 150 minutes weekly moderate-intensity
- Low-impact activities preferred
- Interval training to manage fatigue
Balance Training
- Tai Chi or yoga (modified)
- Dance therapy (Parkinson's programs adapted)
- Physical therapy-guided balance exercises
Resistance Training
- Light resistance 2-3 times weekly
- Focus on major muscle groups
- Avoid overexertion
- Counseling for depression and anxiety
- Support groups for patients and caregivers
- Cognitive-behavioral therapy
- Mindfulness and stress management
Mobility Aids
- Canes for early disease
- Walkers for moderate disease
- Wheelchairs for advanced disease
- Powered wheelchairs for complete mobility assistance
Orthotics
- Ankle-foot orthoses (AFOs) for foot drop
- Knee braces for stability
- Custom splints for contracture prevention
Communication Aids
- Speech-generating devices
- Eye-tracking communication systems
- Tablet-based communication apps
¶ Monitoring and Follow-Up
| Assessment |
Frequency |
| Neurologic examination |
Every 3-6 months |
| Pulmonary function (FVC) |
Every 3-6 months |
| Functional scales (ALSFRS-R) |
Every 3-6 months |
| Nutritional status |
Every 3-6 months |
| Depression screening |
Every 6 months |
PLS progression typically follows a predictable pattern:
| Stage |
Time |
Features |
| Early |
0-3 years |
Leg spasticity, gait difficulty |
| Middle |
3-7 years |
Upper limb involvement, dysarthria |
| Advanced |
7-15 years |
Severe disability, dysphagia, respiratory compromise |
- Home modifications for accessibility
- Assistive technology for daily activities
- Driving evaluation and adaptations
- Respite care services
- Caregiver education and training
- Support groups for caregivers
- Discussion of long-term care preferences
- Advance directives
- Durable power of attorney
¶ Research and Clinical Trials
¶ Active Trial Landscape
Several trials are investigating PLS-specific treatments:
- Edaravone for PLS: Phase 3 trial design published
- ASOs for genetic PLS: Targeting specific mutations when identified
- Stem cell trials: Early-phase trials for motor neuron replacement
Clinical trial information available at:
The prognosis for PLS is generally more favorable than ALS:
- Life expectancy: Near-normal or only modestly reduced
- Progression rate: Very slow, typically decades to severe disability
- Cause of death: Respiratory complications in advanced disease
- Quality of life: Significantly impacted by spasticity and disability
Approximately 10-15% of patients initially diagnosed with PLS will develop lower motor neuron involvement and be reclassified as having ALS.
- Begin baclofen or tizanidine for spasticity
- Start physical therapy
- Evaluate for assistive devices
- Address pseudobulbar affect if present
- Monitor respiratory function
- Optimize spasticity medications
- Consider botulinum toxin for focal spasticity
- Add occupational therapy
- Evaluate for dysarthria/dysphagia
- Consider respiratory support
- Maximize supportive care
- Consider feeding tube if needed
- Initiate non-invasive ventilation if indicated
- Focus on quality of life
- Palliative care consultation